USPTO serial 99182288
KAMADA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 26, 2026
- Examiner
- FOSDICK, GEOFFREY A
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KAMADA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ben Natter
Ben Natter Haug Partners, LLP745 Fifth AvenueNew York, NY 10151United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals, namely, plasma derived and recombinant immunoglobulins for use in the treatment of infectious diseases, namely, CMV disease, Hepatitis B, Varicella Zoster, and rabies, Hematologic conditions including Idiopathic Thrombocytopenic Purpura; Respiratory conditions including Alpha-1 Antitrypsin Deficiency, Obstetrics and Gynecology conditions such as hemolytic disease of the newborn, Transplantation treatments including solid-organ transplants and hematopoietic stem-cell transplantation; pharmaceuticals namely plasma derived and recombinant proteins for treating pulmonary diseases, congenital Alpha-1 Antitrypsin deficiency, post-exposure prophylaxis against viral infection, preventing and treating immune tolerance based diseases, treating immunological disorders and treating inflammatory diseases; pharmaceuticals namely coagulation factors for bleeding disorders; plasma-derived protein preparations for therapeutic use; vaccines; pharmaceutical preparations for the treatment of lung diseases; pharmaceutical preparations for the treatment or prevention of thromboembolic disorders; pharmaceutical preparations for anesthesia analgesia for surgery; pharmaceutical preparations for treatment of CMV infection and disease; pharmaceutical preparations for the treatment of Varicella Zoster Virus; pharmaceutical preparations for treatment of Hepatitis; pharmaceutical preparations for the treatment of Rabies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 26, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 26, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 26, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 26, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 7, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 7, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 1, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 11, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 9, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 9, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 9, 2026 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Dec 18, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 18, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 18, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 12, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 11, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 11, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 26, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 26, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 23, 2025 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Sep 23, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 13, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 13, 2025 | NWAP | NEW APPLICATION ENTERED | — |